Beauty Health Co (NASDAQ:SKIN), the parent company of Hydrafacial, presented its first quarter 2025 results on May 8, revealing a 14.5% year-over-year revenue decline amid ongoing transformation efforts under new leadership. While the company’s stock initially fell 12.68% in regular trading following the announcement, it partially recovered in after-hours trading, rising 12.9% to $1.40.
Quarterly Performance Highlights
Beauty Health reported Q1 2025 net sales of $69.6 million, down 14.5% compared to the same period last year, though exceeding analyst expectations of $63.78 million. The results showed a stark contrast between delivery systems and consumables performance. Delivery systems net sales plummeted 43.5% year-over-year to $20.2 million, while consumables net sales grew 8.2% to $49.4 million, highlighting the company’s shift toward a more recurring revenue model.
As shown in the following financial highlights from the presentation, the company reported a net loss of $10.1 million, a $9.4 million decline from the previous year, while adjusted EBITDA improved to $7.3 million, up $6.9 million year-over-year:
Despite the revenue decline, Beauty Health’s gross margin improved significantly to 69.8% from 59.4% in the prior year. The company’s cash position remains strong at $373 million, providing financial flexibility for its strategic initiatives.
The detailed financial reconciliations reveal the components contributing to the adjusted EBITDA improvement, including reductions in operating expenses:
Strategic Initiatives
Under new leadership, Beauty Health is implementing a comprehensive transformation strategy focused on three key priorities: enhancing commercial execution, accelerating science-backed innovation, and deepening provider partnerships.
The company highlighted significant progress in restructuring its operations, including the appointment of a new Chief Supply Chain & Operations Officer, Chief Revenue Officer, and Chief Marketing Officer. Management reported a reduction in operating expenses of over $30 million year-over-year and a realignment of manufacturing capacity.
As illustrated in the presentation, the company’s strategic focus aims to address current challenges while positioning for future growth:
CEO Marla Beck emphasized these priorities during the earnings call, stating, "Our focus remains anchored on our three priorities: enhancing commercial execution, accelerating science-backed innovation, and deepening provider partnerships."
The company also detailed its transformative progress under the new leadership team:
Competitive Industry Position
Despite current financial challenges, Beauty Health maintains a strong competitive position in the aesthetic industry. The company claims the #1 market share position in its category with over 35,000 devices installed globally and 64% market share in the U.S. microdermabrasion category.
As shown in the following slide, the company operates in a growing market with favorable trends:
The presentation highlighted impressive brand metrics, including a 39% brand awareness, 96% "Worth It" rating on RealSelf, and a 52 Consumer Net Promoter Score. These indicators suggest strong consumer acceptance despite the company’s current financial performance challenges.
The company’s flagship Hydrafacial brand continues to show strong consumer engagement:
Beauty Health also emphasized the clinical efficacy of its treatments, presenting data showing significant improvements in skin conditions after both single treatments and treatment series:
Forward-Looking Statements
Beauty Health provided updated guidance for 2025, projecting second-quarter net sales between $71-76 million and adjusted EBITDA of $2-4 million. For the full year, the company expects net sales of $270-300 million and adjusted EBITDA of $15-25 million.
The detailed guidance is presented in the following slide:
Management noted several challenges ahead, including an additional $5 million in tariff costs expected to impact the second half of 2025 and the transition of China distribution to a third-party model. Market softness in day spas and plastic surgery channels was also acknowledged as a potential headwind.
Despite these challenges, CFO Mike Bonahan expressed confidence in the company’s trajectory, stating during the earnings call, "We’re positioning the company to return to growth," while highlighting strategic initiatives to drive long-term shareholder value.
The company’s business model continues to leverage its large device footprint to drive recurring consumables revenue, which showed resilience with 8.2% growth despite macroeconomic pressures:
While Beauty Health faces near-term headwinds, particularly in device sales, the company’s strong market position, brand metrics, and strategic restructuring efforts under new leadership provide potential pathways for recovery as it continues its transformation journey.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.